Suramin inhibits PDGF-stimulated receptor phosphorylation, proteoglycan synthesis and glycosaminoglycan hyperelongation in human vascular smooth muscle cells

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 7, 2013, Pages 1055-1063

  Little, Peter J ^a,b   Rostam, Muhamad Ashraf ^a   Piva, Terrence J ^b   Getachew, Robel ^a   Kamato, Danielle ^a   Guidone, Daniel ^a   Ballinger, Mandy L ^c   Zheng, Wenhua ^d   Osman, Narin ^a,c  

^a Division of Biosciences   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c RMIT UNIVERSITY   (Australia)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

atherosclerosis; biglycan; imatinib; PDGF receptor kinase activity; PDGF receptor phosphorylation

Indexed keywords

GLYCOSAMINOGLYCAN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEOGLYCAN; SURAMIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PHOSPHORYLATION; PROTEOGLYCAN SYNTHESIS; SMOOTH MUSCLE FIBER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GLYCOSAMINOGLYCANS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; PROTEOGLYCANS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SURAMIN;

EID: 84878802630     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12064     Document Type: Article

References (38)

1. Takano S, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 10: 2654-2660.
2. Warn R, et al. HGF/SF induces mesothelial cell migration and proliferation by autocrine and paracrine pathways. Exp Cell Res 2001; 2: 258-266.
3. Beindl W, et al. Inhibition of receptor/G protein coupling by suramin analogues. Mol Pharmacol 1996; 2: 415-423.
4. Docampo R, Moreno SN,. Current chemotherapy of human African trypanosomiasis. Parasitol Res 2003; 90 (Suppl. 1): S10-S13.
5. Winthrop KL, et al. River blindness: an old disease on the brink of elimination and control. J Glob Infect Dis 2011; 2: 151-155.
6. Liu X, et al. The role of ATP signaling in the migration of intermediate neuronal progenitors to the neocortical subventricular zone. Proc Natl Acad Sci U S A 2008; 33: 11802-11807.
7. Hosang M,. Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 1985; 3: 265-273.
8. Kopp R, Pfeiffer A,. Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res 1990; 20: 6490-6496.
9. Powis G, et al. Inhibition of growth factor binding and intracellular Ca2+ signalling by dextran sulfates of different sizes and degrees of sulfation. Cancer Chemother Pharmacol 1992; 6: 483-486.
10. Ip JH, et al. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 7: 1667-1687.
11. Hu Y, et al. Inhibition of neointima hyperplasia of mouse vein grafts by locally applied suramin. Circulation 1999; 8: 861-868.
12. Schachner T,. Pharmacologic inhibition of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg 2006; 5: 1065-1072.
13. Wight TN,. Proteoglycans in pathological conditions: atherosclerosis. Fed Proc 1985; 2: 381-385.
14. Williams KJ, Tabas I,. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 5: 551-561.
15. Little PJ, et al. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vascular Health Risk Management 2007; 3: 117-124.
16. Little PJ, et al. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opinion Lipidology 2008; 19: 448-454.
17. Anggraeni VY, et al. Correlation of C4ST-1 and ChGn-2 expression with chondroitin sulfate chain elongation in atherosclerosis. Biochem Biophys Res Commun 2011; 1: 36-41.
18. Ballinger ML, et al. Regulation of glycosaminoglycan structure and atherogenesis. Cell Mol Life Sci 2004; 11: 1296-1306.
19. Ballinger ML, et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic lipid deposition in vivo. J Cell Mol Med 2010; 14: 1408-1418.
20. Ehrenstein MR, et al. Statins for atherosclerosis-as good as it gets? N Engl J Med 2005; 1: 73-75.
21. Little PJ, et al. Cellular and cytokine-based inflammatory processes as novel therapeutic targets for the prevention and treatment of atherosclerosis. Pharmacol Ther 2011; 3: 255-268.
22. Schonherr E, et al. Genistein selectively inhibits platelet-derived growth factor- stimulated versican biosynthesis in monkey arterial smooth muscle cells. Arch Biochem Biophys 1997; 2: 353-361.
23. Mundschau LJ, et al. Platelet-derived growth factor (PDGF) induction of egr-1 is independent of PDGF receptor autophosphorylation on tyrosine. J Biol Chem 1994; 23: 16137-16142.
24. Plattner R, et al. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 1999; 18: 2400-2411.
25. Getachew R, et al. PDGF beta-receptor kinase activity and ERK1/2 mediate glycosaminoglycan elongation on biglycan and increases binding to LDL. Endocrinology 2010; 9: 4356-4367.
26. Neylon CB, et al. Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)amiloride- sensitive Na(+)- and HCO3(-)-dependent mechanism. Circ Res 1990; 4: 814-825.
27. Nigro J, et al. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 2002; 1: 119-129.
28. Little PJ, et al. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol 2002; 1: 55-60.
29. Tannock LR, et al. Glucosamine supplementation accelerates early but not late atherosclerosis in LDL receptor-deficient mice. J Nutr 2006; 11: 2856-2861.
30. Potter-Perigo S, et al. Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from beta-D-xyloside inhibition of proliferation. Arch Biochem Biophys 1992; 1: 101-109.
31. Getachew R, et al. Characterisation of Ki11502 as a potent inhibitor of PDGF beta receptor-mediated proteoglycan synthesis in vascular smooth muscle cells. Eur J Pharmacol 2010; 2-3: 186-192.
32. Weber H, et al. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin. J Clin Invest 1994; 2: 788-798.
33. Silbert CK, et al. Production of [3H]hexosamine-labeled proteoglycans by cultures of normal and diabetic skin fibroblasts: dilution of exogenous [3H]glucosamine by endogenous hexosamine from glucose and other sources. Arch Biochem Biophys 1989; 1: 393-397.
34. Silbert JE, Sugumaran G,. Biosynthesis of chondroitin/dermatan sulfate. IUBMB Life 2002; 4: 177-186.
35. Little PJ, et al. Biosynthesis of natural and hyperelongated chondroitin sulfate glycosaminoglycans: new insights into an elusive process. Open Biochem J 2008; 2: 135-142.
36. Kinsella MG, et al. Selective expression and processing of biglycan during migration of bovine aortic endothelial cells. The role of endogenous basic fibroblast growth factor. J Biol Chem 1997; 1: 318-325.
37. Little PJ, et al. Genistein inhibits PDGF-stimulated proteoglycan synthesis in vascular smooth muscle without blocking PDGFbeta receptor phosphorylation. Arch Biochem Biophys 2012; 1: 25-31.
38. Burch ML, et al. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor. J Biol Chem 2010; 35: 26798-26805.